MetaCap

Atossa Therapeutics (ATOS) vs Psyence Biomedical (PBM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Atossa Therapeutics (ATOS) has outperformed Psyence Biomedical (PBM) over the past year, losing 86.4% versus a loss of 94.9%. Atossa Therapeutics is the larger company by market cap ($15.9 million vs $15.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATOS-86.37%PBM-94.90%
+27%-37%-102%
Nov 21, 20251 yearNov 20, 2026
ATOS-94.71%PBM-100.00%
+25%-41%-106%
Dec 6, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATOS versus PBM key metrics
MetricATOSPBM
Share price$1.60$2.97
Market cap$15.92M$15.80M
1-day change-8.86%+3.85%
YTD return-81.98%-89.90%
1-year return-86.37%-94.90%
5-year return-95.34%—
EPS (TTM)$-3.92$-12.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-34.77M$1.01M
52-week high$14.85$73.44
52-week low$1.59$1.92
Distance from 52-week high-89.26%-95.96%
Analyst consensusstrong_buy—
Avg. price target upside+1091.22%—
Average volume68.00K61.93K
Shares outstanding9.98M5.32M
Employees1612
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Atossa Therapeutics

ATOS stock →

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

About Psyence Biomedical

PBM stock →

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

ATOS vs PBM FAQ

Which is bigger, Atossa Therapeutics or Psyence Biomedical?

Atossa Therapeutics (ATOS) is larger, with a market capitalization of $15.92M compared with $15.80M for Psyence Biomedical (PBM).

Which stock has performed better over the past year, ATOS or PBM?

ATOS returned -86.37% over the past 12 months, compared with -94.90% for PBM (price return, excluding dividends). Past performance does not predict future results.

Are Atossa Therapeutics and Psyence Biomedical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons